Management of recurrent epithelial ovarian carcinoma

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 45, Issue 4, 2005, Pages 269-277

  Vasey, Paul A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

CA125; Chemotherapy; Ovarian carcinoma; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG POTENTIATION; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; INFECTION; MEDICAL DECISION MAKING; MONOTHERAPY; NEUROPATHY; NEUROTOXICITY; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SURGICAL TECHNIQUE;

ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARIECTOMY; PLATINUM COMPOUNDS; PROTEINS;

EID: 23744491020     PISSN: 00048666     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2005.00438.x     Document Type: Review

References (38)

1. Vergote I, Rustin GJS, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours (ovarian cancer). Gynecologic Cancer Intergroup. J. Nat. Cancer Inst. 2000; 92: 1534-1535.
2. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during followup according to CA125: a North Thames ovary group study. Ann. Oncol. 1996; 7: 361-364.
3. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br. J. Cancer 1989; 59: 650-653.
4. Markman M, Rothman R, Hakes T et al. Second-line platinum chemotherapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991; 9: 389-393.
5. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 1990; 36: 207-211.
6. Zanotti KM, Belinson JL, Kennedy AW, Webster KD et al. Treatment of relapsed carcinoma of the ovary with single agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol. Oncol. 2000; 79: 211-215.
7. Bolis G, Scargone G, Giarkina G et al. Carboplatin alone vs carboplatin plus epidoxirubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol. Oncol. 2000; 81: 3-9.
8. Cantu MG, Buda A, Parma G et al. Randomised controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 2002; 20: 1232-1237.
9. Parmer MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
10. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomised phase III trial of the AGO OVAR, the NCIC CTG and the EORTC. J. Clin. Oncol. 2004; 22 (S14): Abstract 5005.
11. Vasey PA, Jayson GC, Gordon A, Gabra H et al. Scottish Gynaecological Cancer Trials Group. Phase III randomised trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2004; 96: 1682-1691.
12. Ferrero JM, Weber B, Lepille D et al. Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (> 6 months) relapse (AOCLR): survival results of a GINECO phase II trial. Clin. Oncol. 2004; 22 (S14): Abstract 5022.
13. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analog of taxol. J. Natl Cancer Inst 1991; 83: 288-291.
14. Viens P, Petit T, Yovine P et al. Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: final results. J. Clin. Oncol. 2004; 22 (S14): Abstract 5023.
15. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann. Oncol. 2001; 12: 1705-1709.
16. van der Burg M, de Wit R, van putten WL et al. Weekly cisplatin and daily etoposide is highly effective in platinum pretreated ovararian cancer. Br. J. Cancer 2002; 86: 19-25.
17. Bruzzone M, Mencoboni M, Mammoliti F et al. Secondline chemotherapy with vepesid (VP16) in platinum resistant advanced ovarian cancer patients. J. Clin. Oncol. 2004; 22 (S14): Abstract 5082.
18. van der Berg M, Vergote I, Burger CW et al. Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. J. Clin. Oncol. 2004; 22 (S14): Abstract 5058.
19. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int. J. Oncol. 1999; 15: 1233-1238.
20. Muggia F, Kim E, Downey K, McCaffrey K, Green R, Ho MF. Safety of prolonged Doxil administration in recurrent gynaecologic cancers. J. Clin. Oncol. 2004; 22 (S14): Abstract 5055.
21. O'Byrne K, Bliss P, Graham JD et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer. 2002 American Society of Clinical Oncology Annual Meeting Proceedings; Abstract 808.
22. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent ovarian cancer. J. Clin. Oncol. 1997; 15: 2183-2193.
23. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001; 19: 3312-3322.
24. Gordon AN, Teitelbaum A and the 30-49 Study Group. Overall survival advantage for pegylated liposomal doxorubicin compared with topotecan in recurrent epithelial ovarian cancer. Presented at the 12th meeting of the Federation of European Cancer Societies (ECCO 12), 22 Sept. 2003, Copenhagen, Denmark.
25. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 1995; 13: 1584-1588.
26. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest 1994; 94: 70370-8.
27. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell fines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 2000; 16: 555-560.
28. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20: 1248-1259.
29. Segna RA, Dottino PR, Mandelli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 1993; 11: 434-439.
30. Vaccarello L, Rubin SC, Vlamis V et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynaecol. Oncol. 1995; 57: 61-65.
31. Berek JS, Bertelsen K, du Bois, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 1999; 10 (S1): 87-92.
32. Gadducci A, Iacconi P, Fanucchi A, Cosio S, Miccoli P, Gennazanni AR. Survival after intestinal obstruction in patients with fatal ovarian cancer analysis of prognostic factors. Int. J. Gynecol. Cancer 1998; 8: 177-182.
33. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001; (1): CD001034.
34. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol. 1990; 76: 258-263.
35. Markman M, Webster K, Zanotti K, Rohl J, Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-Volume ovarian cancer. Gynecol. Oncol. 2004; 93: 390-393.
36. Giaccone G, Johnson DH, Manegold C et al. A phase III clinical trial of ZD1839 (IRESSA) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced nonsmall cell lung cancer (INTACT I). Ann. Oncol. 2002; 13 (S5).
37. Gatzemeier U, Pluzanska A, Szczesna E et al. Results of a phase III trial of erlotinib (OSI774) combined with cisplatin and gemcitabine chemotherapy in advanced nonsmall cell lung cancer. J. Clin. Oncol. 2004; 22: (S14), Abstract 7010.
38. Herbst RS, Prager D, Hermann R et al. A phase III trial of erlotinib HC1 (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2004; 22 (S14): Abstract 7011.